NCT04195750 2025-04-29A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Merck Sharp & Dohme LLCPhase 3 Active not recruiting755 enrolled 28 charts 1 FDA
NCT04489771 2025-02-11MK-6482-013Merck Sharp & Dohme LLCPhase 2 Active not recruiting154 enrolled 19 charts